Neuropace (NPCE)

• Market cap: $381M
• 1 day: 4.22%
• 5 days: 8.50%
• 1 month: -1.94%
• 3 months: -17.76%
• 6 months: 82.13%
• Year to date: 0.35%
• 1 year: -14.12%
• 5 years: -53.45%
• 10 years: -53.45%
• Sector: Healthcare
• Industry: Medical Devices

About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Employees: 184

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

2,500% more call options, than puts

Call options by funds: $260K | Put options by funds: $10K

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

126% more capital invested

Capital invested by funds: $103M [Q3] → $234M (+$130M) [Q4]

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

29% more funds holding

Funds holding: 48 [Q3] → 62 (+14) [Q4]

19.24% more ownership

Funds ownership: 50.67% [Q3] → 69.91% (+19.24%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 46% upside
• Avg. target: $18.50 59% upside
• High target: $20 72% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn 27% 1-year accuracy 12 / 45 met price target	72% upside $20	Overweight Maintained	5 Mar 2025
Wells Fargo Larry Biegelsen 27% 1-year accuracy 12 / 45 met price target	46% upside $17	Overweight Maintained	30 Jan 2025